Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) EPS (Basic) (2016 - 2025)

International Stem Cell (ISCO) has disclosed EPS (Basic) for 16 consecutive years, with $0.01 as the latest value for Q2 2025.

  • On a quarterly basis, EPS (Basic) fell 43.16% to $0.01 in Q2 2025 year-over-year; TTM through Sep 2025 was -$0.01, a 79.48% increase, with the full-year FY2024 number at -$0.03, down 50.0% from a year prior.
  • EPS (Basic) was $0.01 for Q2 2025 at International Stem Cell, up from -$0.03 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.03 in Q2 2021 to a low of -$0.08 in Q1 2021.
  • A 5-year average of -$0.01 and a median of -$0.01 in 2023 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 12106.0% in 2023; the steepest drop was 1243.48% in 2023.
  • International Stem Cell's EPS (Basic) stood at -$0.04 in 2021, then surged by 108.75% to $0.0 in 2022, then tumbled by 1243.48% to -$0.04 in 2023, then soared by 103.75% to $0.0 in 2024, then skyrocketed by 658.33% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's EPS (Basic) are $0.01 (Q2 2025), -$0.03 (Q1 2025), and $0.0 (Q4 2024).